Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel versus androgen receptor–targeted therapy in metastatic castration-resistant prostate cancer
2014-004676-29Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jun 2015
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Cabazitaxel + prednisone with Enzalutamide or abiraterone acetate + prednisone (2 arms). Primary endpoint: Radiographic progression-free survival. Started Jun 2015; status: completed.
02
Drugs
cabazitaxelenzalutamideabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2014-004676-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004676-29.